Zenith Technologies has reported 400 per cent growth in its Chinese operations in the last 3 years.
The company now has a presence working on sites across five Chinese cities – Shanghai, Suzhou, Xi’an, Hangzhou & Guangzhou - and employs a growing team to work across its client base supporting pharma and biotech companies with the implementation of technologies to improve manufacturing efficiencies such as Automation, IT, Manufacturing Execution Systems (MES) and Digital and Data Analysis.
With the Chinese life sciences market currently set as the world’s second largest national market, and with an expected value of $220 billion by 2022, Zenith plans to double its operations in the country over the next three years and expand its work with local companies as well as continuing to support global multinationals.
“The Chinese market has been leading the way in revolutionary cell therapy innovations, which are changing the face of medicine delivery,” Liang Zhou, General Manager of Greater China said. “There is growing interest in the adoption of automating processes in this area as companies build a new generation of facilities in line with stringent international standards with a view to supplying across the world.
Zenith’s success in China represents the company’s latest endeavor in the Asian market having first set up a presence on the continent in 2002 with the opening of its regional headquarters in Singapore.
In 2008 the company set up an office in India, which now hosts more than 100 employees and serves as a global support hub to deliver software projects anywhere in the world, featuring a remote engineering center and 24/7 IT support desk service.